Neurotyping Platform for MDD
Major Depressive Disorder
DevelopmentActive
Key Facts
About Universal Brain
Universal Brain is an early-stage neuroscience and AI company aiming to revolutionize the diagnosis and treatment of depression through objective, brain-based biomarkers. Its core platform, Neurotique™, combines a proprietary EEG headset with digital event-related potential (ERP) tasks and algorithms to subtype patients based on functional neural measures, moving beyond subjective symptom reporting. The company's initial focus is on reducing heterogeneity in clinical trials and aiding clinician decision-making, with the long-term goal of establishing a new data-driven standard in psychiatry.
View full company profileTherapeutic Areas
Other Major Depressive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Accelerated Deep TMS Protocol | BrainsWay | FDA Cleared |
| ZURZUVAE (zuranolone) | Sage Therapeutics | Phase 3 |
| MDD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| NMDAR Antagonist (GM-2505/Bretisilocin) | Gilgamesh Pharmaceuticals | Phase 2 |
| Neuroplastogen (GM-1020) | Gilgamesh Pharmaceuticals | Phase 2a |
| NA-901 | Biomed | Phase 2B/3 |
| SP-624 (Forvisirvat) | Arrivo BioVentures | Phase 2 |
| NBS System for MDD | Nexstim | Approved |
| Major Depressive Disorder Studies | Noesis Pharma Clinical Trials | Phase 2-4 |
| Depression Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| CLE-100 | Clexio Biosciences | Phase 2 |
| Proliv™Rx | Neurolief | Phase 2 |